Phase II/III Study of AZD2816, for the Prevention of COVID-19 in Adults - AZD2816

Study identifier:D7220C00001

ClinicalTrials.gov identifier:NCT04973449

EudraCT identifier:2021-002530-17

CTIS identifier:N/A

Study Complete

Official Title

A Phase II/III Partially Double-Blinded, Randomised, Multinational, Active-Controlled Study in Both Previously Vaccinated and Unvaccinated Adults to Determine the Safety and Immunogenicity of AZD2816, a Vaccine for the Prevention of COVID-19 Caused by Variant Strains of SARS-CoV-2

Medical condition

COVID-19

Phase

Phase 2/3

Healthy volunteers

Yes

Study drug

-

Sex

All

Actual Enrollment

2843

Study type

Interventional

Age

18 Years - 115 Years

Date

Study Start Date: 27 Jun 2021
Primary Completion Date: 04 Feb 2022
Study Completion Date: 02 Aug 2022

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Prevention

Verification:

Verified 01 Aug 2023 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria